DiagnaMed Expects Brain Health AI Platform To Be Commercialized In Q4 2023

FULL DISCLOSURE: This is sponsored content for DiagnaMed Holdings.

DiagnaMed Holdings (CSE: DMED) is anticipating to begin the commercialization stage of its flagship CERVAI brain health AI platform in the fourth quarter of 2023.

The timeline estimate was provided by the company in an announcement this morning, which indicated that they expect the tool to be available at health centers, pharmacies, hospitals, clinics, doctors offices, and homes. Commercial support tools are in the process of being finalized, while discussions with clinics and research centres across North America are currently underway.

The platform currently consists of a Brain Age Estimation as well as a Brain Health Assessment tool, the latter of which includes an electroencephalogram headset and machine-learning model. The assessment tool generates a brain health score and clinician-observed measures to enable users to be proactive with their brain health. The mHealth & eHealth Development and Innovation Centre was reportedly hired to integrate the assessment service of CERVAI into what is recognized as Canada’s Digital Health Technology Access Centre.

READ: DiagnaMed Launches Dr. GenAI, A Generative AI Medical Chatbot

The current Brain Age model meanwhile predicts chronological ages with a medium-to-strong statistical effect size based on EEG data recorded from the headset, the data from which is then processed using a proprietary machine-learning model. The final phase of development of the Brain Age program is said to be complete, with final results from the clinic and home studies slated to be published later this year to support commercialization.

“We are in the final stage of development for CERVAI™, our novel brain health AI platform. We expect to launch CERVAI™ in Q4-2023. CERVAI™ is for people who want to take control of their brain health,” commented CEO Fabio Chianelli.

DiagnaMed Holdings last traded at $0.04 on the CSE.


FULL DISCLOSURE: DiagnaMed Holdings is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of DiagnaMed Holdings. The author has been compensated to cover DiagnaMed Holdings on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Leave a Reply

Video Articles

Endeavour Mining Q1 Earnings: Cash Flow Is King

G Mining Oko West Feasibility: Move Fast, Break.. Nothing?

New Gold Q1 Earnings: What’s Behind The Market’s Surprising Reaction?

Recommended

First Majestic Posts Record Cash Flows In Q1 As Production Costs Fall

Brazil Potash Secures Funding In Support Of US$2.5 Billion Autozales Project

Related News

DiagnaMed Enhances CERVAI Brain Health Platform Commercialization Efforts In Canada

DiagnaMed Holdings (CSE: DMED) continues to progress with the commercialization of its CERVAI Brain Health...
Tuesday, March 12, 2024, 09:19:18 AM

DiagnaMed Launches Brain Age Brain Health AI Tool In Canada

DiagnaMed Holdings (CSE: DMED) has officially launched its Brain Age Brain Health AI solution in...
Tuesday, April 23, 2024, 09:22:20 AM

DiagnaMed Focuses On Brain Health AI Platform Development

DiagnaMed Holdings (CSE: DMED) appears to be going all in on artificial intelligence. The drug...

Tuesday, February 14, 2023, 08:04:57 AM

DiagnaMed Brings AI To Brain Health — With Fabio Chianelli And Dr. John Kounios

Joining us today on the Daily Dive is that of DiagnaMed Holdings (CSE: DMED) Chairman...

Wednesday, March 1, 2023, 01:30:00 PM

DiagnaMed Unveils First Commercial AI Product For Healthcare Industry, FormGPT

DiagnaMed Holdings (CSE: DMED) has launched its first commercial product under its initiative to bring...
Wednesday, May 3, 2023, 08:28:00 AM